SCHEMBL23748324

SCHEMBL23748324

C=CCCc1ccccc1C(O)c1ccncc1

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP3A4 P08684 2/20 0.36
CYP1A2 P05177 1/20 0.36
CYP2D6 P10635 1/20 0.36
CYP2C9 P11712 1/20 0.36
CYP2C19 P33261 1/20 0.36
CYP17A1 P05093 1/20 0.35
CYP19A1 P11511 1/20 0.35
CYP11B1 P15538 1/20 0.35
CYP11B2 P19099 1/20 0.35
GAA P10253 1/20 0.34
SLC6A2 P23975 3/20 0.33
SLC6A4 P31645 3/20 0.33
SLC6A3 Q01959 3/20 0.33
CYP51A1 Q16850 1/20 0.33
SMN1; SMN2 Q16637 2/20 0.33
KDM4E B2RXH2 1/20 0.33
HSD17B10 Q99714 1/20 0.33
IDO1 P14902 1/20 0.30
LMNA P02545 1/20 0.30
L3MBTL1 Q9Y468 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23748253 0.88 MEN1 (0.39) CYP2C9CYP2C19SLC6A2SLC6A4SLC6A3
SCHEMBL23748138 0.83 SMN1; SMN2 (0.44) CYP3A4CYP1A2CYP2D6CYP2C9CYP2C19
SCHEMBL23748259 0.83 SMN1; SMN2 (0.44) CYP3A4CYP1A2CYP2D6CYP2C9CYP2C19
SCHEMBL23748287 0.82 SLC6A2 (0.33) SLC6A2SLC6A4SLC6A3CYP51A1
SCHEMBL23748161 0.78 MAPT (0.43) CYP3A4CYP1A2CYP2D6CYP2C9SLC6A2
SCHEMBL23748218 0.72 SMN1; SMN2 (0.38) CYP2D6CYP2C9CYP2C19CYP11B1CYP11B2
SCHEMBL23748201 0.72 CTSA (0.31)
SCHEMBL24353892 0.71 GABRA1 (0.42) CYP1A2CYP2D6CYP2C9CYP2C19SLC6A2
SCHEMBL23003623 0.69 CYP3A4 (0.48) CYP3A4CYP1A2CYP2D6CYP2C9CYP2C19
SCHEMBL23882759 0.67 HDAC4 (0.47) CYP3A4CYP1A2CYP2D6CYP2C9CYP2C19

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230002409-A1 MACROCYCLIC FLU ENDONUCLEASE INHIBITORS JANSSEN BIOPHARMA INC (US) 2023-01-05 US disclosed
US-11312727-B1 Macrocyclic flu endonuclease inhibitors Janssen Biopharma, Inc. (US) 2022-04-26 US disclosed
EP-3864020-A1 MACROCYCLIC FLU ENDONUCLEASE INHIBITORS Janssen BioPharma, Inc. (US) 2021-08-18 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230002409-A1 MACROCYCLIC FLU ENDONUCLEASE INHIBITORS ACE, PNP, FEN1 CYP3A4 88/4885CYP1A2 157/4885CYP2D6 185/4885
US-11312727-B1 Macrocyclic flu endonuclease inhibitors ACE, FEN1, PNP CYP3A4 88/4885CYP1A2 96/4885CYP2D6 156/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.